A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events.
Br J Cancer
; 129(4): 612-619, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37419999
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Guideline
Limits:
Humans
Language:
En
Journal:
Br J Cancer
Year:
2023
Type:
Article
Affiliation country:
Canada